Design of the POSSIBLE US™ Study: postmenopausal women’s compliance and persistence with osteoporosis medications
暂无分享,去创建一个
[1] T. Weiss,et al. Osteoporosis practice patterns in 2006 among primary care physicians participating in the NORA study , 2007, Osteoporosis International.
[2] J. Cramer,et al. A systematic review of persistence and compliance with bisphosphonates for osteoporosis , 2007, Osteoporosis International.
[3] S. Silverman,et al. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: The risedronate and alendronate (REAL) cohort study , 2006, Osteoporosis International.
[4] S. Silverman,et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. , 2006, Mayo Clinic proceedings.
[5] G. Oster,et al. Compliance with drug therapy for postmenopausal osteoporosis , 2006, Osteoporosis International.
[6] D. Gold. Medication Adherence , 2006, Journal of managed care pharmacy : JMCP.
[7] Krista F Huybrechts,et al. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. , 2006, Bone.
[8] K. Kahler,et al. Adherence and Persistence Associated with the Pharmacologic Treatment of Osteoporosis in a Managed Care Setting , 2006, Southern medical journal.
[9] A. Westfall,et al. Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users , 2006, Osteoporosis International.
[10] B. Ettinger,et al. Persistence with weekly alendronate therapy among postmenopausal women , 2006, Osteoporosis International.
[11] S. Giannini,et al. Determinants of adherence to osteoporosis treatment in clinical practice , 2006, Osteoporosis International.
[12] R. Recker,et al. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. , 2005, Mayo Clinic proceedings.
[13] A. Scillitani,et al. Osteoporosis intervention in ambulatory patients with previous hip fracture: a multicentric, nationwide Italian survey , 2005, Osteoporosis International.
[14] R. Stafford,et al. National trends in osteoporosis visits and osteoporosis treatment, 1988-2003. , 2004, Archives of internal medicine.
[15] Krista F. Huybrechts,et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice , 2004, Osteoporosis International.
[16] M. Atkinson,et al. Health and Quality of Life Outcomes , 2004 .
[17] G. Herrero-Beaumont,et al. Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: An open-label, prospective, nonrandomized, observational study. , 2004, Clinical therapeutics.
[18] J. Mccombs,et al. Compliance with drug therapies for the treatment and prevention of osteoporosis. , 2003, Maturitas.
[19] S. Silverman. The Osteoporosis Assessment Questionnaire (OPAQ): A reliable and valid disease-targeted measure of health-related quality of life (HRQOL) in osteoporosis , 2000, Quality of Life Research.
[20] S. Ish-shalom,et al. Compliance of osteoporotic patients with different treatment regimens. , 2003, The Israel Medical Association journal : IMAJ.
[21] S. Emani,et al. Compliance with pharmacologic therapy for osteoporosis , 2003, Osteoporosis International.
[22] K. McCoy,et al. Tolerability and compliance with risedronate in clinical practice , 2003, Osteoporosis International.
[23] E. Barrett-Connor,et al. Design of NORA, the National Osteoporosis Risk Assessment Program: a longitudinal US registry of postmenopausal women. , 1998, Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.
[24] J. Adachi. Current treatment options for osteoporosis. , 1996, The Journal of rheumatology. Supplement.
[25] R. Brooks. EuroQol: the current state of play. , 1996, Health policy.